Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Rapid Communication - Journal of Cancer Immunology & Therapy (2024) Volume 7, Issue 5

The interplay between tumor cells and the immune system.

Wengen Yu*

Department of Dermatology, Sun Yat-sen University, China

*Corresponding Author:
Wengen Yu
Department of Dermatology, Sun Yat-sen University, China
E-mail: weng.yu@163.com

Received: 27-Sep -2024, Manuscript No. AAJCIT-24-150272; Editor assigned: 28-Sep-2024, PreQC No. AAJCIT-24-150272 (PQ); Reviewed:14-Oct-2024, QC No. AAJCIT-24-150272; Revised:19-Oct-2024, Manuscript No. AAJCIT-24-150272 (R); Published:28-Oct-2024, DOI:10.35841/aara-7.5.232

Citation: Yu W., The interplay between tumor cells and the immune system. J Cancer Immunol Ther. 2024;7(5):232

Visit for more related articles at Journal of Cancer Immunology & Therapy

Introduction

The relationship between tumor cells and the immune system is complex and dynamic, fundamentally influencing cancer progression, metastasis, and patient outcomes. Tumors have evolved intricate mechanisms to evade immune detection and destruction, leading to immune suppression and promoting tumor survival. Conversely, the immune system can recognize and eliminate tumor cells, highlighting the importance of understanding this interplay in developing effective cancer therapies. This article explores the mechanisms through which tumor cells evade immune responses, the role of the immune system in tumor surveillance, and current therapeutic strategies that leverage this interaction [1].

Tumors employ several strategies to evade the immune system, which can be categorized into immunoediting, immunosuppression, and antigen loss. This process refers to the selective pressure exerted by the immune system on tumor cells, leading to the emergence of variants that can survive immune attack. Initially, the immune system can recognize and eliminate tumor cells; however, through immunoediting, resistant variants can arise that may express lower levels of target antigens or other changes that diminish their visibility to the immune system [2].

Tumors can create a local immune-suppressive microenvironment by secreting cytokines and other factors that inhibit immune responses. For example, tumor-associated macrophages (TAMs) often adopt an immunosuppressive phenotype, secreting anti-inflammatory cytokines such as IL-10 and TGF-β, which can inhibit T cell activation and promote regulatory T cell (Treg) development [3].

Some tumor cells may lose or downregulate the expression of specific antigens recognized by the immune system, rendering them less detectable. This antigenic modulation can occur through genetic mutations or epigenetic changes, allowing tumor cells to escape immune surveillance. The immune system constantly patrols the body for abnormal cells, including those that may become cancerous. This process, known as immune surveillance, involves various immune cells, including cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and macrophages, which can recognize and destroy cancer cells [4].

Tumor cells can express unique or overexpressed antigens, known as tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), which can be recognized by the immune system. For instance, proteins derived from mutated oncogenes or tumor suppressor genes can serve as TSAs, prompting an immune response [5].

The complex interplay between tumor cells and the immune system has led to the development of several innovative therapeutic strategies aimed at enhancing anti-tumor immunity. Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have revolutionized cancer therapy by blocking inhibitory pathways that dampen T cell responses. By unleashing T cells from these checkpoints, these therapies have demonstrated significant efficacy in various cancers, including melanoma, lung cancer, and renal cell carcinoma [6].

Therapeutic cancer vaccines aim to enhance the immune response against tumor antigens. By stimulating the immune system to recognize and attack tumor cells, these vaccines can provide a more targeted and sustained immune response. For example, sipuleucel-T, a vaccine for prostate cancer, has shown effectiveness in clinical trials [7].

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a groundbreaking approach for treating hematologic malignancies. By engineering T cells to express receptors that specifically target tumor antigens, CAR-T therapy has achieved remarkable success in treating diseases like acute lymphoblastic leukemia and certain lymphomas [8].

Combining different immunotherapies or combining immunotherapy with conventional treatments, such as chemotherapy or radiation, is an active area of research. This approach aims to enhance anti-tumor responses and overcome the immunosuppressive microenvironment often created by tumors [9].

When tumor antigens are presented on major histocompatibility complex (MHC) molecules by antigen-presenting cells (APCs), they can activate T cells and generate a robust adaptive immune response. Helper T cells promote the activation of CTLs, which can directly kill tumor cells, while B cells produce antibodies targeting tumor antigens [10].

Conclusion

The interplay between tumor cells and the immune system is a dynamic and complex relationship that plays a critical role in cancer progression and treatment outcomes. Understanding the mechanisms of immune evasion and the various ways the immune system can recognize and eliminate tumor cells has led to significant advancements in cancer therapies. Immune checkpoint inhibitors, cancer vaccines, CAR-T cell therapy, and combination approaches are transforming the landscape of cancer treatment, offering hope to patients with previously limited options. Continued research into the intricacies of this interplay will pave the way for new therapeutic strategies and improved outcomes for cancer patients.

References

  1. Shen H, Yang ES, Conry M, Fiveash J, Contreras C, Bonner JA, Shi LZ. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Gen Dis. 2019;6(3):232-46.

    2. Indexed at, Google Scholar

  2. Grizzi G, Caccese M, Gkountakos A, Carbognin L, Tortora G, Bria E, Pilotto S. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. Expert Rev Mol Diagn. 2017;17(12):1055-69.

    3. Google Scholar

  3. Kreiter S, Vormehr M, Van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nat. 2015;520(7549):692-6.

    4. Google Scholar

  4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nat. 2011;480(7378):480-9.

    5. Indexed at, Google Scholar

  5. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Sci. 2015;348(6230):124-8.

    6. Google Scholar

  6. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nat. 2017;547(7662):222-6.

    7. Google Scholar

  7. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Sci. 2015;348(6230):69-74.

    8. Indexed at, Google Scholar

  8. Nebhan CA, Johnson DB. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Rev Anticancer Ther. 2020;20(2):137-45.

    9. Google Scholar

  9. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Sci. 2015;350(6257):207-11.

    10. Indexed at, Google Scholar

  10. Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. Pathogenetic features and current management of glioblastoma. Cancers. 2021;13(4):856.

    11. Indexed at, Google Scholar

Get the App